Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

Lara, PN; Douillard, JY; Nakagawa, K; von Pawel, J; McKeage, Mark; Albert, I; Losonczy, G; Reck, M; Heo, DS; Fan, X; Fandi, A; Scagliotti, G

dc.contributor.author	Lara, PN	en
dc.contributor.author	Douillard, JY	en
dc.contributor.author	Nakagawa, K	en
dc.contributor.author	von Pawel, J	en
dc.contributor.author	McKeage, Mark	en
dc.contributor.author	Albert, I	en
dc.contributor.author	Losonczy, G	en
dc.contributor.author	Reck, M	en
dc.contributor.author	Heo, DS	en
dc.contributor.author	Fan, X	en
dc.contributor.author	Fandi, A	en
dc.contributor.author	Scagliotti, G	en
dc.coverage.spatial	United States	en
dc.date.accessioned	2012-03-06T19:20:38Z	en
dc.date.issued	2011	en
dc.identifier.citation	Journal of Clinical Oncology 29(22):2965-2971 2011	en
dc.identifier.issn	0732-183X	en
dc.identifier.uri	http://hdl.handle.net/2292/13078	en
dc.description.abstract	This phase III trial was conducted to test whether the novel vascular disrupting agent ASA404 (vadimezan), when combined with first-line platinum-based chemotherapy, improves survival in patients with advanced non-small-cell lung cancer (NSCLC) versus chemotherapy alone.	en
dc.language	eng	en
dc.publisher	American Society of Clinical Oncology	en
dc.relation.ispartofseries	Journal of Clinical Oncology	en
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/0732-183X/	en
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm	en
dc.subject	Adult	en
dc.subject	Aged	en
dc.subject	Angiogenesis Inhibitors	en
dc.subject	Antineoplastic Combined Chemotherapy Protocols	en
dc.subject	Carboplatin	en
dc.subject	Carcinoma, Non-Small-Cell Lung	en
dc.subject	Disease-Free Survival	en
dc.subject	Double-Blind Method	en
dc.subject	Drug Administration Schedule	en
dc.subject	Female	en
dc.subject	Humans	en
dc.subject	Kaplan-Meier Estimate	en
dc.subject	Lung Neoplasms	en
dc.subject	Male	en
dc.subject	Middle Aged	en
dc.subject	Neoplasm Staging	en
dc.subject	Odds Ratio	en
dc.subject	Paclitaxel	en
dc.subject	Quality of Life	en
dc.subject	Questionnaires	en
dc.subject	Treatment Failure	en
dc.subject	Xanthones	en
dc.title	Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.	en
dc.type	Journal Article	en
dc.identifier.doi	10.1200/JCO.2011.35.0660	en
pubs.issue	22	en
pubs.begin-page	2965	en
pubs.volume	29	en
dc.rights.holder	Copyright: American Society of Clinical Oncology	en
dc.identifier.pmid	21709202	en
pubs.end-page	2971	en
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.subtype	Article	en
pubs.elements-id	213944	en
pubs.org-id	Medical and Health Sciences	en
pubs.org-id	Medical Sciences	en
pubs.org-id	Pharmacology	en
pubs.org-id	Science	en
pubs.org-id	Science Research	en
pubs.org-id	Maurice Wilkins Centre (2010-2014)	en
dc.identifier.eissn	1527-7755	en
dc.identifier.pii	JCO.2011.35.0660	en
pubs.record-created-at-source-date	2012-02-15	en
pubs.dimensions-id	21709202	en